Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma

Autor: Markus Munder, Hartmut Goldschmidt, Hans Salwender, Marc S. Raab, Jana Schlenzka, Martin Goerner, Marc-Andrea Baertsch, Martin Hoffmann, Peter Brossart, Dirk Hose, Anna Jauch, Jan Dürig, Stephan Fuhrmann, Steffen Luntz, Christina Kunz, Jens Hillengaß, Hans-Walter Lindemann, Kai Neben, Elias K. Mai, Henk M. Lokhorst, Thomas Hielscher, Ulrich Dührsen, Igor Wolfgang Blau, Hans Martin, Mathias Hänel, Pieter Sonneveld, Christof Scheid, Katja Weisel, Uta Bertsch, Helga Bernhard, Anja Seckinger, Britta Besemer
Přispěvatelé: German-Speaking Myeloma Multicenter Group (GMMG), Hematology, Basic (bio-) Medical Sciences, Anatomy and neurosciences
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Oncology
Male
medicine.medical_specialty
Phase iii trials
Hematopoietic Stem Cell Transplantation/methods
Transplantation
Autologous/methods
Medizin
Myeloma
Antineoplastic Agents
lcsh:RC254-282
Transplantation
Autologous
Article
Maintenance Chemotherapy
Bortezomib
Autologous stem-cell transplantation
Medical research
Internal medicine
medicine
Internal Medicine
Humans
Immunologic Factors
In patient
ddc:610
Lenalidomide
Multiple myeloma
Retrospective Studies
business.industry
hematology
Antineoplastic Agents/therapeutic use
Hematopoietic Stem Cell Transplantation
Maintenance Chemotherapy/methods
Middle Aged
medicine.disease
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Immunologic Factors/therapeutic use
Clinical trial
Multiple Myeloma/therapy
Lenalidomide/therapeutic use
Cohort
Bortezomib/therapeutic use
Female
business
Multiple Myeloma
medicine.drug
Zdroj: Blood Cancer Journal
German-Speaking Myeloma Multicenter Group (GMMG) 2021, ' Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma ', Blood cancer journal, vol. 11, no. 1, 1 . https://doi.org/10.1038/s41408-020-00390-3
Blood Cancer Journal, 11(1):1. Nature Publishing Group
Blood cancer journal, 11(1):1. Nature Publishing Group
Blood Cancer Journal, Vol 11, Iss 1, Pp 1-10 (2021)
ISSN: 2044-5385
DOI: 10.1038/s41408-020-00390-3
Popis: Lenalidomide (LEN) maintenance (MT) post autologous stem cell transplantation (ASCT) is standard of care in newly diagnosed multiple myeloma (MM) but has not been compared to other agents in clinical trials. We retrospectively compared bortezomib (BTZ; n = 138) or LEN (n = 183) MT from two subsequent GMMG phase III trials. All patients received three cycles of BTZ-based triplet induction and post-ASCT MT. BTZ MT (1.3 mg/m2 i.v.) was administered every 2 weeks for 2 years. LEN MT included two consolidation cycles (25 mg p.o., days 1–21 of 28 day cycles) followed by 10–15 mg/day for 2 years. The BTZ cohort more frequently received tandem ASCT (91% vs. 33%) due to different tandem ASCT strategies. In the LEN and BTZ cohort, 43% and 46% of patients completed 2 years of MT as intended (p = 0.57). Progression-free survival (PFS; HR = 0.83, p = 0.18) and overall survival (OS; HR = 0.70, p = 0.15) did not differ significantly with LEN vs. BTZ MT. Patients with n = 54 vs. BTZ: n = 84), LEN MT significantly improved PFS (HR = 0.61, p = 0.04) but not OS (HR = 0.46, p = 0.09). In conclusion, the significant PFS benefit after eliminating the impact of different tandem ASCT rates supports the current standard of LEN MT after ASCT.
Databáze: OpenAIRE
Externí odkaz: